Capital Raising

OPEN

GRETALS Australia

“From our own botanical source to a cognitive health solution: the MEMORISE™ neurodegeneration programme.”
High-purity natural (2S)-pinocembrin.
I am interested

INDUSTRY

Biotech & Life Sciences

RAISING

$3,000,000

MINIMUM INVESTMENT

$25,000

Investment Highlights

Transaction Overview

Company Overview

Products & Services

Team

Transaction Summary
GRETALS Australia 

Raising: $3M

Minimum Investment $25,000

Request Further Information

Investment Highlights

Proprietary supply and extraction of natural (2S)-pinocembrin from Key Variety plantations owned by Gretals, with >98% chiral purity independently confirmed by a leading Australian research institution.

Focused on the pre-symptomatic stage of neurodegeneration, which blood-based pTau-217 biomarker testing is starting to make measurable, and which current antibody therapies do not address.

Active preclinical programmes with the University of Adelaide/SARDI and University of Auckland (sheep Alzheimer’s model) and the Menzies Institute (MND/FTD).

Injectable formulation with Monash University that has met its key development milestones and allows pathway to securing intellectual property rights.

Transaction Overview

Terms of offer:

Issue of 2,400,000 fully paid ordinary shares in GRETALS Australia Limited, an unlisted Australian
public company, at AU$1.25 per share to raise up to AU$3,000,000.


Open to wholesale and sophisticated investors only (s708 Corporations Act 2001 (Cth) and
equivalent exemptions in other jurisdictions). No prospectus or product disclosure statement will
be issued.


New shares rank equally with existing ordinary shares. After the issue, new investors will hold 8.28%* of the 28,970,527 shares on issue, and existing shareholders will hold 91.72%.
MEMORISE™ Investment Proposition (Sept 2026).

* Assumes the offer is fully subscribed. Does not include the potential exercise of 800,000 options held by executives and key consultants, expiring 30 June 2028. On a fully diluted basis, assuming all options are exercised, new investors would hold 8.06%.

USE OF FUNDS

Research programmes - committed research with the University of Melbourne, the Menzies Institute (University of Tasmania) and SARDI through Q4 2027, continuation of existing preclinical trials, and other R&D on flavanone applications with a focus on antimicrobial resistance (AMR) solutions

50%
Fill Counter

product development and regulatory - NDIN and TGA approvals for pinocembrin as a supplement ingredient

Intellectual property and compliance - patent attorney and filings, accounting and audit, other compliance

Team and operations - CEO, Financial Officer, Operations Manager, overheads and programme contingency

8%
Fill Counter
7%
Fill Counter
20%
Fill Counter

AMR business development and testing

Other expenses and contingencies

8%
Fill Counter
7%
Fill Counter

Percentages are of the AU$3,000,000 gross raise.

The allocation above is indicative only. It is based on 18-month forward expenditure estimates and reflects the Board’s current plans for a fully subscribed raise. Actual expenditure may differ materially. GRETALS reserves the right to reallocate funds between categories, and across its research and development programmes, as results, opportunities, costs and the amount raised require. If the offer is not fully subscribed, funds will be applied according to the Board’s priorities.

Company Overview

star

Australian unlisted public company developing MEMORISE™, a neurodegeneration programme built on natural-source (2S)-pinocembrin, a plant flavonoid.

Lightning

IP position built on trade secrets over the botanical source, cultivation and chiral purification, supported by a patent portfolio that includes pending applications.

Research delivered through university and institute partners: University of Adelaide/SARDI, University of Auckland, Menzies Institute (University of Tasmania),
Monash University, Swinburne University and the University of Melbourne.

symbol

Board experienced in life sciences, capital markets, GMP manufacturing and tax/M&A, supported by a Scientific Advisory Committee established in 2018.

Capital Structure & Key Investors

Capital structure as at 30 September 2026: 26,570,527 shares on issue, comprising 22,570,527 ordinary shares and 4,000,000 Class A shares held by Kenworthy Investment Services (15.05%).

Products & Services

MEMORISE™ is a development programme. No product is currently on the market.

  • MEMORISE™ capsule and Linguet® sublingual troche – lead formats in development for the
    Listed Medicine (Australia) and dietary supplement (US) pathways.
  • MEMORISE™ injectable liposomal formulation – preclinical; formulation developed with Monash
    University; intended as a licensable prescription asset.
  • Further delivery formats – intranasal (under evaluation at the Menzies Institute), transdermal
    patch and functional beverage, all at early stage.
  • Research-grade (2S)-pinocembrin – potential supply from existing inventory to academic and
    commercial research partners.

Team

  • BOARD

Alistair Cumming

Founder, Chief Executive Officer & Director                       

Trevor Easterbrook

Finance & Governance Director                                                                           

Dr Grant Richards BVSc

Chief Scientific Director                                                                                                

Leigh O'Gorman

Operations Director                                                                             

Alan Kenworthy

Non-Executive Director                                                                              

GRETALS reserves the right, subject to applicable law and the PrimaryMarkets Platform Rules, to vary the terms of the offer (including the offer size, timing and closing date), to close the offer early, to accept or scale back applications in whole or in part, or to withdraw the offer at any time before shares are issued. GRETALS may also raise capital by other means, including through alternative offers, during or after this offer, and on terms that may differ from this offer.

General Disclaimer

The content on this site is provided solely for information purposes, is not a recommendation or an offer to buy or sell a security and is not warranted to be correct, complete or accurate. This site is intended for Accredited/Sophisticated/Wholesale investors only. By continuing with an investment, you are self-accrediting that you so qualify. To the extent permitted by law, neither PrimaryMarkets, its affiliates, nor the content providers (such as the issuers of securities who appear on the site) are responsible for any investment decisions, damages or losses resulting from, or related to, the content, data and analyses or their use. The investment opportunities on this site and any statements made about them by their issuers are not vetted or verified by PrimaryMarkets. Investing in securities in private or unlisted companies and Funds is speculative and involves a high degree of risk. The investor must be prepared to withstand a total loss of their investment. We strongly encourage the investor to seek independent financial, professional or investment advice before investing in securities. The presence of an investment opportunities on this site should not be interpreted as an implied endorsement of it by PrimaryMarkets. Some content provided may constitute a summary or extract of another document. Past performance does not necessarily indicate future performance. The content on this site was current as at date of initial publication but may not be current as at the date of your viewing. For a more complete understanding of all the terms and conditions of your use of this site click here.

Want to learn more?

Fill in the expression of interest form below